Maxim Group Downgrades Pulse Biosciences (NASDAQ:PLSE) to Hold

Maxim Group downgraded shares of Pulse Biosciences (NASDAQ:PLSEGet Rating) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning, The Fly reports.

Separately, StockNews.com assumed coverage on shares of Pulse Biosciences in a research note on Saturday, September 17th. They set a sell rating on the stock.

Pulse Biosciences Stock Up 7.2 %

PLSE stock opened at $1.49 on Wednesday. Pulse Biosciences has a 12-month low of $1.18 and a 12-month high of $24.58. The company has a market cap of $55.32 million, a price-to-earnings ratio of -0.74 and a beta of 1.97. The company has a 50 day moving average of $1.58 and a two-hundred day moving average of $2.48.

Pulse Biosciences (NASDAQ:PLSEGet Rating) last released its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). Pulse Biosciences had a negative return on equity of 186.19% and a negative net margin of 2,866.34%. The company had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.55 million. During the same quarter in the previous year, the company earned ($0.57) EPS. On average, research analysts anticipate that Pulse Biosciences will post -1.71 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Occudo Quantitative Strategies LP increased its stake in shares of Pulse Biosciences by 217.3% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock worth $54,000 after purchasing an additional 39,981 shares during the last quarter. Millennium Management LLC acquired a new position in Pulse Biosciences in the 2nd quarter valued at $184,000. TIAA FSB acquired a new position in Pulse Biosciences in the 2nd quarter valued at $42,000. Westside Investment Management Inc. grew its stake in Pulse Biosciences by 41.4% in the 2nd quarter. Westside Investment Management Inc. now owns 178,195 shares of the company’s stock valued at $272,000 after buying an additional 52,166 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Pulse Biosciences by 5.1% in the 1st quarter. Bank of America Corp DE now owns 820,390 shares of the company’s stock valued at $3,988,000 after buying an additional 39,645 shares during the last quarter. Institutional investors and hedge funds own 8.34% of the company’s stock.

About Pulse Biosciences

(Get Rating)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Featured Articles

The Fly logo

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.